Targeting Focal Adhesion Kinase Suppresses the Malignant Phenotype in Rhabdomyosarcoma Cells
Despite the tremendous advances in the treatment of childhood solid tumors, rhabdomyosarcoma (RMS) continues to provide a therapeutic challenge. Children with metastatic or relapsed disease have a disease-free survival rate under 30%. Focal adhesion kinase (FAK) is a nonreceptor tyrosine kinase that...
Main Authors: | Alicia M. Waters, Laura L. Stafman, Evan F. Garner, Smitha Mruthyunjayappa, Jerry E. Stewart, Elizabeth Mroczek-Musulman, Elizabeth A. Beierle |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2016-08-01
|
Series: | Translational Oncology |
Online Access: | http://www.sciencedirect.com/science/article/pii/S1936523316300481 |
Similar Items
-
Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma
by: Alicia M. Waters, et al.
Published: (2016-10-01) -
Focal Adhesion Kinase Inhibition Contributes to Tumor Cell Survival and Motility in Neuroblastoma Patient-Derived Xenografts
by: Laura L. Stafman, et al.
Published: (2019-09-01) -
PP2A activation alone and in combination with cisplatin decreases cell growth and tumor formation in human HuH6 hepatoblastoma cells.
by: Laura L Stafman, et al.
Published: (2019-01-01) -
FTY720 Decreases Tumorigenesis in Group 3 Medulloblastoma Patient-Derived Xenografts
by: Evan F. Garner, et al.
Published: (2018-05-01) -
Targeting PIM Kinases Affects Maintenance of CD133 Tumor Cell Population in Hepatoblastoma
by: Laura L. Stafman, et al.
Published: (2019-02-01)